148 related articles for article (PubMed ID: 26405213)
1. A two-pronged attack against mantle cell lymphoma.
Steidl C
Blood; 2015 Sep; 126(13):1521-3. PubMed ID: 26405213
[TBL] [Abstract][Full Text] [Related]
2. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.
Bhatt S; Matthews J; Parvin S; Sarosiek KA; Zhao D; Jiang X; Isik E; Letai A; Lossos IS
Blood; 2015 Sep; 126(13):1555-64. PubMed ID: 26194763
[TBL] [Abstract][Full Text] [Related]
3. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based therapy for mantle cell lymphoma.
Munger CM; Vose JM; Joshi SS
Int J Oncol; 2006 Jun; 28(6):1337-43. PubMed ID: 16685434
[TBL] [Abstract][Full Text] [Related]
6. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma.
Friedberg JW
Best Pract Res Clin Haematol; 2012 Jun; 25(2):131-2. PubMed ID: 22687448
[No Abstract] [Full Text] [Related]
9. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
10. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
[TBL] [Abstract][Full Text] [Related]
11. Indolent mantle cell lymphoma.
Hsi ED; Martin P
Leuk Lymphoma; 2014 Apr; 55(4):761-7. PubMed ID: 23927395
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide for mantle cell lymphoma.
Skarbnik AP; Goy AH
Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system.
Visser HP; Tewis M; Willemze R; Kluin-Nelemans JC
Leukemia; 2000 Aug; 14(8):1483-9. PubMed ID: 10942246
[TBL] [Abstract][Full Text] [Related]
14. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract][Full Text] [Related]
15. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
16. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
18. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
Ferrero S; Pastore A; Scholz CW; Forstpointner R; Pezzutto A; Bergmann L; Trümper L; Finke J; Keller U; Ghione P; Passera R; Hiddemann W; Weigert O; Unterhalt M; Dreyling M
Leukemia; 2016 Apr; 30(4):984-7. PubMed ID: 26242461
[No Abstract] [Full Text] [Related]
[Next] [New Search]